# Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

> **NCT00725881** · PHASE1,PHASE2 · COMPLETED · sponsor: **Diffusion Pharmaceuticals Inc** · enrollment: 48 (actual)

## Conditions studied

- Intermittent Claudication

## Interventions

- **DRUG:** Trans sodium crocetinate (TSC)
- **DRUG:** 0.9% normal saline

## Key facts

- **NCT ID:** NCT00725881
- **Lead sponsor:** Diffusion Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725881, "Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00725881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*